Abstract
The discovery of the immunosuppressive properties of cyclosporin A (CSA) and its successful utilisation in organ transplantation was a milestone in clinics. CSA has revolutionised transplantation both in term of efficiency and quality-of-life of the patient. In addition, the analysis of the mode of action of CSA has been rewarding in the understanding the mecha-nisms leading to T lymphocytes activation. CSA binds to a family of cytosolic receptors, the cyclophilins, a highly conserved family of proteins. Once this complex is formed, a third protein, the calcineurin, is recruited. The calcineurin, a calcium-dependent phosphatase, loose its activity when complexed. Dephosphorylation of NFAT, a substrate of calcineurin is a mandatory step for its translocation to the nucleus where NFAT acts as a transactivator involved in the regulation of the genes encoding many cytokines. CSA preventing NFAT dephosphorylation blocks cytokine production this in turn allowing for a better engrafting. The resolution of the tertiary structure of CSA alone or complexed with cyclophilin and calcineurin has important implication in the modelling of new drugs devoid of its side effects. Indeed, the high incidence of cancer is one of the main problems linked to CSA utilisation. Recent data suggest that CSA may promote cancer inducing the transcription of the gene encoding transforming growth factor b. Other molecules sharing with CSA its immunosuppressive activity were later described. Some of them, as FK506, have the some mode of action; others, as rapamycin, mycophenolate mofetil or leflunomide, act at different steps of T cell activation.
Keywords: immunosuppressive durgs, T cell activation, cyclosporin A CSA, dephosphorylation, rapamycin, cyclophilins, CSA receptors, calcineurin, t lymphocyte activation, IL2 gene expression, CSA FK506 sensitive, apoptosis, thymic selection, tridimensional structure, immunosuppressor immunophilin complex, mycobhenolate mofetil MM
Current Medicinal Chemistry
Title: The Impact of Immunosuppressive Drugs on the Analysis of T-Cell Activation
Volume: 7 Issue: 7
Author(s): Paula Rovira, Laurent Mascarell and Paolo Truffa Bachi
Affiliation:
Keywords: immunosuppressive durgs, T cell activation, cyclosporin A CSA, dephosphorylation, rapamycin, cyclophilins, CSA receptors, calcineurin, t lymphocyte activation, IL2 gene expression, CSA FK506 sensitive, apoptosis, thymic selection, tridimensional structure, immunosuppressor immunophilin complex, mycobhenolate mofetil MM
Abstract: The discovery of the immunosuppressive properties of cyclosporin A (CSA) and its successful utilisation in organ transplantation was a milestone in clinics. CSA has revolutionised transplantation both in term of efficiency and quality-of-life of the patient. In addition, the analysis of the mode of action of CSA has been rewarding in the understanding the mecha-nisms leading to T lymphocytes activation. CSA binds to a family of cytosolic receptors, the cyclophilins, a highly conserved family of proteins. Once this complex is formed, a third protein, the calcineurin, is recruited. The calcineurin, a calcium-dependent phosphatase, loose its activity when complexed. Dephosphorylation of NFAT, a substrate of calcineurin is a mandatory step for its translocation to the nucleus where NFAT acts as a transactivator involved in the regulation of the genes encoding many cytokines. CSA preventing NFAT dephosphorylation blocks cytokine production this in turn allowing for a better engrafting. The resolution of the tertiary structure of CSA alone or complexed with cyclophilin and calcineurin has important implication in the modelling of new drugs devoid of its side effects. Indeed, the high incidence of cancer is one of the main problems linked to CSA utilisation. Recent data suggest that CSA may promote cancer inducing the transcription of the gene encoding transforming growth factor b. Other molecules sharing with CSA its immunosuppressive activity were later described. Some of them, as FK506, have the some mode of action; others, as rapamycin, mycophenolate mofetil or leflunomide, act at different steps of T cell activation.
Export Options
About this article
Cite this article as:
Rovira Paula, Mascarell Laurent and Bachi Truffa Paolo, The Impact of Immunosuppressive Drugs on the Analysis of T-Cell Activation, Current Medicinal Chemistry 2000; 7 (7) . https://dx.doi.org/10.2174/0929867003374778
DOI https://dx.doi.org/10.2174/0929867003374778 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry B Cell Responses to Oxidative Stress
Current Pharmaceutical Design Chemokines as Novel Therapeutic Targets in Autoimmune Thyroiditis
Recent Patents on DNA & Gene Sequences The Recent Progress in RSV Vaccine Technology
Recent Patents on Anti-Infective Drug Discovery Targeting the STAT Pathway in Head and Neck Cancer: Recent Advances and Future Prospects
Current Cancer Drug Targets Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Peroxisome Proliferator-Activated Receptors and the Control of Inflammation
Current Drug Targets - Inflammation & Allergy Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Current Vascular Pharmacology Natural Coumarins as a Novel Class of Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Protein Kinase Inhibitors: Current Strategies and Future Prospects (Executive Guest Editor: Julio Caballero)]
Current Pharmaceutical Design Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Current Topics in Medicinal Chemistry No Zinc Deficiency But a Putative Immunosuppressive Role for Labile Zn in Patients with Systemic Autoimmune Disease
Current Rheumatology Reviews The Xiaogu San Attenuates Pain and Cartilage Damage in Rats with Monosodium Iodoacetate Induced Osteoarthritis
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Acute Hepatitis C: Epidemiology, Pathogenesis and Therapy (Executive Editor: Paolo Fabris) ]
Current Pharmaceutical Design The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Fibrin Clot Properties and Cardiovascular Disease
Vascular Disease Prevention (Discontinued)